High rates of culture conversion and low loss to follow-up in MDR-TB patients managed at Regional Referral Hospitals in Uganda

Table 4 Frequency of adverse events and how they were resolved (N = 53)

Adverse event	Reaction n (%)	How adverse events were resolved
Adverse event	Reaction n (%)	Managed clinically	Regimen changed	Other^b
Nausea/vomiting	14 (20.3%)	14 (100%)
Headache	15 (21.7%)	15 (100%)
Diarrhea	2 (2.9%)	2 (100%)
Burning pains in the lower limbs	20 (29.0%)	18 (90%)	1 (5%)	1 (5%)
Arthralgia	12 (17.4%)	12 (100%)
Seizures	1 (1.4%)	1 (100%)
Rash	1 (1.4%)	1 (100%)
Psychiatric manifestations^a	9 (13.0%)	9 (100%)
Hypothyroidism	2 (2.9%)	2 (100%)
Visual disturbances (Reduced visual acuity)	10 (14.5%)	10 (100%)
Hearing disturbance (Bilateral mild through to profound hearing loss)	21 (30.4%)	21 (100%)
Dizziness	13 (18.8%)	13 (100%)

^aPsychiatric manifestations were spectrum of mental disorders as described by WHO including among others bad dreams, convulsions, suicidal thoughts, insomnia, headaches, anxiety, nervousness, memory or mood changes
^b“Other” referred to the other ways the patient with an adverse event was managed other than regimen change or clinical management. In this case, the one patient was just reassured by the clinician that the adverse event would eventually self-resolve and encouraged to continue taking their medication for MDR-TB

ISSN: 1471-2334